Marburg, Germany, 01 May 2017
sterna biologicals GmbH & Co. KG ("sterna biologicals") is pleased to announce that two of its co-founders, Prof. Dr. Holger Garn and Prof. Dr. Harald Renz, were selected to receive this year's Paul Martini Prize. The prize is one of the most prestigious prizes in the field of medicine in Germany and is awarded by the Paul Martini Foundation for exceptional research achievements in the development of novel clinically relevant therapeutic approaches. The prize will be awarded today on the occasion of the 123rd Congress of the German Society for Internal Medicine in Mannheim.

Marburg, Germany, 17 May 2015

• SB010 Phase IIa proof-of-concept results published in the New England Journal of Medicine
• SB010 Phase I programme results published in the Journal of Allergy and Clinical Immunology
• SB010 development programme comprising four completed clinical trials demonstrates excellent safety profile combined with efficacy comparable to monoclonal antibodies

Marburg, Germany, 10 October 2016

• Paper summarizing role of GATA-3 in ulcerative colitis published in Gastroenterology
• SECURE study of SB012 in patients with moderate to severe ulcerative colitis continues to progress (NCT02129439)

sterna biologicals GmbH & Co. KG ("sterna biologicals") announced today that detailed mechanistic investigations of the role of GATA-3 in ulcerative colitis, performed primarily by Prof Markus Neurath's group in Erlangen (Germany), were published in Gastroenterlogy (Popp et al, 2016).

Marburg, Germany, 3 Sept 2014

• German Center for Lung Research (DZL) to conduct investigator-initiated trial of SB010 in patients with eosinophilic COPD
• Further data from Phase IIa trial of SB010 in asthmatic patients to be presented at the European Respiratory Society International Congress 2014 in Munich, Germany